IP Library Patent Application 17375237
Patent Application
App. No. 17/375,237

HIGH-CONTENT IMAGING OF MICROFLUIDIC DEVICES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/375,237
Abstract

The present invention is related to high-content microscopy imaging of microfluidic cell culture systems. A method of high-content microfluidic device microscopy is contemplated. along with related statistical analysis and microfluidic device adaptors.

Claims (71)

1 . A method of imaging microfluidic devices comprising:

(a) providing a microfluidic device comprising a porous membrane, said porous membrane separating a first microfluidic channel having an endothelial cell layer and a second microfluidic channel having a second cell layer;

(b) providing a microscope capable of image acquisition;

(c) taking a first set of microscopic image acquisitions;

(d) determining a focal height and locating a standard coordinate system from said first set of microscopic image acquisitions, wherein the coordinate system is located based on the location of the membrane within the microfluidic device; and

(e) taking a second set of microscopic image acquisitions based on the coordinate system located in the first set of microscopic acquisitions;

wherein said second set of microscopic image acquisitions comprise said endothelial cell layer and said second cell layer together, separated by the membrane.

2 . The method of claim 1 , wherein the microscope is a confocal microscope.

3 . The method of claim 1 , wherein the first set of microscopic acquisitions are low-resolution.

4 . The method of claim 1 , wherein the second set of microscopic acquisitions are high-resolution.

5 . (canceled)

6 . The method of claim 4 , wherein the second set of microscope acquisitions are used to evaluate the effect of an agent on the cells.

7 . The method of claim 6 , wherein the agent is a pharmaceutical.

8 . The method of claim 1 , wherein the cells are cultured for more than seven days.

9 . (canceled)

10 . The method of claim 4 , wherein the second set of microscopic acquisitions comprises a three-dimensional acquisition.

11 . (canceled)

12 . The method of claim 1 , wherein the second cell layer comprises liver cells.

13 . The method of claim 12 , wherein the liver cells are hepatocytes.

14 . The method of claim 13 , wherein the hepatocytes are human hepatocytes.

15 . The method of claim 1 , wherein the second cell layer comprises kidney cells.

16 . (canceled)

17 . (canceled)

18 . The method of claim 1 , further comprising applying flow to the channels.

19 . The method of claim 1 , wherein the second set of acquisitions, guided by the coordinate system, comprises Z stack slices through different layers of the microfluidic device.

20 - 37 . (canceled)

38 . A method of imaging microfluidic devices comprising:

(a) providing a microfluidic device comprising a membrane having pores, said membrane separating two microfluidic channels;

(b) providing a microscope capable of image acquisition;

(c) taking a set of low resolution microscopic image acquisitions;

(d) locating a standard coordinate system using said set of low resolution image acquisitions, wherein the coordinate system is located based on the location of said pores; and

(e) taking a set of high resolution microscopic acquisitions based on the coordinate system located in the first set of microscopic acquisitions.

39 - 61 . (canceled)

62 . The method of claim 38 , wherein the microfluidic device is seeded with cells.

63 . The method of claim 62 , wherein the high resolution set of microscopic image acquisitions is used to evaluate the effect of an agent on the cells.

64 - 68 . (canceled)

69 . The method of claim 62 , wherein the cells are liver cells.

70 . The method of claim 69 , wherein the liver cells are hepatocytes and sinusoidal endothelial cells.

71 . (canceled)

72 . The method of claim 62 , wherein the cells are kidney cells.

73 . The method of claim 62 , wherein the microscopic acquisitions are of individual cells.

74 . (canceled)

75 . The method of claim 62 , further comprising applying flow to the channels.

76 . The method of claim 75 , where in the flow exerts shear stress on the cells.

77 . A method of analyzing cellular phenotype changes following agent exposure comprising:

(a) providing a plurality of microfluidic devices comprising cells in microchannels, said microchannels comprising microchannel walls;

(b) providing a microscope capable of image acquisition;

(c) treating a number of said microfluidic devices with an agent and a number of said microfluidic devices with a control media;

(d) taking a first set of microscopic acquisitions;

(e) locating a standard coordinate system using the first set of microscope acquisitions, wherein the coordinate system is located based on the location of the microchannel walls within the microfluidic device;

(f) taking a second set of microscopic acquisitions based on the coordinate system located in the first set of microscopic acquisitions;

(g) making endpoint measurements of the acquisitions;

(h) fitting a regression model to the measurements;

(i) estimating a field effect based on the regression; and

(j) comparing the field effect from microfluidic devices treated with an agent verses microfluidic device treated with a control media;

wherein said high resolution microscopic acquisition comprises a three-dimensional microscopic acquisition.

78 . The method of claim 77 , wherein said regression model is a Bayesian linear regression model.

79 . The method of claim 77 , wherein said field effect is a linear field effect.

80 . The method of claim 77 , wherein the microscope is a confocal microscope.

81 . The method of claim 77 , wherein the first set of microscopic acquisitions are low-resolution.

82 . The method of claim 77 , wherein the second set of microscopic acquisitions are high-resolution.

83 . The method of claim 77 , wherein the agent is a pharmaceutical.

84 - 85 . (canceled)

86 . The method of claim 77 , wherein the three-dimensional acquisition comprises an endothelial cell layer and hepatocyte cell layer together, separated by the membrane.

87 . The method of claim 77 , wherein the cells are liver cells.

88 . The method of claim 87 , wherein the liver cells are hepatocytes and sinusoidal endothelial cells.

89 . The method of claim 88 , wherein the hepatocytes and sinusoidal endothelial cells are human hepatocytes and human sinusoidal endothelial cells.

90 . The method of claim 77 , wherein the cells are kidney cells.

91 . The method of claim 77 , wherein the microscopic acquisitions are of individual cells.

92 . The method of claim 77 , further comprising applying flow to the channels.

98 - 110 . (canceled)

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Oct 28, 2025
From: PERCEPTIVE CREDIT HOLDINGS III, LP
To: EMULATE, INC.
Reel/Frame 073365/0249 →
RELEASE OF SECURITY INTEREST Recorded Oct 20, 2025
From: PERCEPTIVE CREDIT HOLDINGS III, LP
To: EMULATE, INC.
Reel/Frame 073116/0888 →
SECURITY AGREEMENT Recorded Sep 15, 2021
From: EMULATE, INC.
To: PERCEPTIVE CREDIT HOLDINGS III, LP, AS ADMINISTRATIVE AGENT
Reel/Frame 057517/0604 →